84 related articles for article (PubMed ID: 28782519)
1. Identification of novel ALK2 inhibitors and their effect on cancer cells.
Kim M; Choi O; Pyo S; Choi SU; Park CH
Biochem Biophys Res Commun; 2017 Oct; 492(1):121-127. PubMed ID: 28782519
[TBL] [Abstract][Full Text] [Related]
2. Bone morphogenetic protein 9 (BMP9) and BMP10 enhance tumor necrosis factor-α-induced monocyte recruitment to the vascular endothelium mainly via activin receptor-like kinase 2.
Mitrofan CG; Appleby SL; Nash GB; Mallat Z; Chilvers ER; Upton PD; Morrell NW
J Biol Chem; 2017 Aug; 292(33):13714-13726. PubMed ID: 28646109
[TBL] [Abstract][Full Text] [Related]
3. Fibroblast growth factor 2 inhibits bone morphogenetic protein 9-induced osteogenic differentiation of mesenchymal stem cells by repressing Smads signaling and subsequently reducing Smads dependent up-regulation of ALK1 and ALK2.
Song T; Wang W; Xu J; Zhao D; Dong Q; Li L; Yang X; Duan X; Liang Y; Xiao Y; Wang J; He J; Tang M; Wang J; Luo J
Int J Biochem Cell Biol; 2013 Aug; 45(8):1639-46. PubMed ID: 23680673
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of ALK2 with bicyclic pyridyllactams.
Witten MR; Wu L; Lai CT; Kapilashrami K; Pusey M; Gallagher K; Chen Y; Yao W
Bioorg Med Chem Lett; 2022 Jan; 55():128452. PubMed ID: 34780900
[TBL] [Abstract][Full Text] [Related]
5. Identification of bone morphogenetic protein 9 (BMP9) as a novel profibrotic factor in vitro.
Muñoz-Félix JM; Cuesta C; Perretta-Tejedor N; Subileau M; López-Hernández FJ; López-Novoa JM; Martínez-Salgado C
Cell Signal; 2016 Sep; 28(9):1252-1261. PubMed ID: 27208502
[TBL] [Abstract][Full Text] [Related]
6. Autocrine bone morphogenetic protein-9 signals through activin receptor-like kinase-2/Smad1/Smad4 to promote ovarian cancer cell proliferation.
Herrera B; van Dinther M; Ten Dijke P; Inman GJ
Cancer Res; 2009 Dec; 69(24):9254-62. PubMed ID: 19996292
[TBL] [Abstract][Full Text] [Related]
7. Novel Quinazolinone Inhibitors of ALK2 Flip between Alternate Binding Modes: Structure-Activity Relationship, Structural Characterization, Kinase Profiling, and Cellular Proof of Concept.
Hudson L; Mui J; Vázquez S; Carvalho DM; Williams E; Jones C; Bullock AN; Hoelder S
J Med Chem; 2018 Aug; 61(16):7261-7272. PubMed ID: 30085668
[TBL] [Abstract][Full Text] [Related]
8. Bone morphogenetic protein‑9 promotes the differentiation of mouse spleen macrophages into osteoclasts via the ALK1 receptor and ERK 1/2 pathways in vitro.
Li H; Zhao D; Wang S; Ding J; Zhao L
Mol Med Rep; 2016 Nov; 14(5):4545-4550. PubMed ID: 27748860
[TBL] [Abstract][Full Text] [Related]
9. ALK2 R206H mutation linked to fibrodysplasia ossificans progressiva confers constitutive activity to the BMP type I receptor and sensitizes mesenchymal cells to BMP-induced osteoblast differentiation and bone formation.
van Dinther M; Visser N; de Gorter DJ; Doorn J; Goumans MJ; de Boer J; ten Dijke P
J Bone Miner Res; 2010 Jun; 25(6):1208-15. PubMed ID: 19929436
[TBL] [Abstract][Full Text] [Related]
10. DNALK2 inhibits the proliferation and invasiveness of breast cancer MDA-MB-231 cells through the Smad-dependent pathway.
Wang K; Sun X; Feng HL; Fei C; Zhang Y
Oncol Rep; 2017 Feb; 37(2):879-886. PubMed ID: 28075462
[TBL] [Abstract][Full Text] [Related]
11. FKBP12 is a major regulator of ALK2 activity in multiple myeloma cells.
Quist-Løkken I; Andersson-Rusch C; Kastnes MH; Kolos JM; Jatzlau J; Hella H; Olsen OE; Sundan A; Knaus P; Hausch F; Holien T
Cell Commun Signal; 2023 Jan; 21(1):25. PubMed ID: 36717825
[TBL] [Abstract][Full Text] [Related]
12. Development of an ALK2-biased BMP type I receptor kinase inhibitor.
Mohedas AH; Xing X; Armstrong KA; Bullock AN; Cuny GD; Yu PB
ACS Chem Biol; 2013; 8(6):1291-302. PubMed ID: 23547776
[TBL] [Abstract][Full Text] [Related]
13. BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis.
Scharpfenecker M; van Dinther M; Liu Z; van Bezooijen RL; Zhao Q; Pukac L; Löwik CW; ten Dijke P
J Cell Sci; 2007 Mar; 120(Pt 6):964-72. PubMed ID: 17311849
[TBL] [Abstract][Full Text] [Related]
14. Activin receptor-like kinase-2 inhibits activin signaling by blocking the binding of activin to its type II receptor.
Renlund N; O'Neill FH; Zhang L; Sidis Y; Teixeira J
J Endocrinol; 2007 Oct; 195(1):95-103. PubMed ID: 17911401
[TBL] [Abstract][Full Text] [Related]
15. Pathogenic mutation of ALK2 inhibits induced pluripotent stem cell reprogramming and maintenance: mechanisms of reprogramming and strategy for drug identification.
Hamasaki M; Hashizume Y; Yamada Y; Katayama T; Hohjoh H; Fusaki N; Nakashima Y; Furuya H; Haga N; Takami Y; Era T
Stem Cells; 2012 Nov; 30(11):2437-49. PubMed ID: 22949078
[TBL] [Abstract][Full Text] [Related]
16. Müllerian inhibiting substance signaling uses a bone morphogenetic protein (BMP)-like pathway mediated by ALK2 and induces SMAD6 expression.
Clarke TR; Hoshiya Y; Yi SE; Liu X; Lyons KM; Donahoe PK
Mol Endocrinol; 2001 Jun; 15(6):946-59. PubMed ID: 11376113
[TBL] [Abstract][Full Text] [Related]
17. BMP9 Induces Cord Blood-Derived Endothelial Progenitor Cell Differentiation and Ischemic Neovascularization via ALK1.
Kim J; Kim M; Jeong Y; Lee WB; Park H; Kwon JY; Kim YM; Hwang D; Kwon YG
Arterioscler Thromb Vasc Biol; 2015 Sep; 35(9):2020-31. PubMed ID: 26229139
[TBL] [Abstract][Full Text] [Related]
18. ALK1Fc Suppresses the Human Prostate Cancer Growth in
Astrologo L; Zoni E; Karkampouna S; Gray PC; Klima I; Grosjean J; Goumans MJ; Hawinkels LJAC; van der Pluijm G; Spahn M; Thalmann GN; Ten Dijke P; Kruithof-de Julio M
Front Cell Dev Biol; 2017; 5():104. PubMed ID: 29259971
[TBL] [Abstract][Full Text] [Related]
19. DLL4/Notch1 and BMP9 Interdependent Signaling Induces Human Endothelial Cell Quiescence via P27KIP1 and Thrombospondin-1.
Rostama B; Turner JE; Seavey GT; Norton CR; Gridley T; Vary CP; Liaw L
Arterioscler Thromb Vasc Biol; 2015 Dec; 35(12):2626-37. PubMed ID: 26471266
[TBL] [Abstract][Full Text] [Related]
20. A novel mutation of ALK2, L196P, found in the most benign case of fibrodysplasia ossificans progressiva activates BMP-specific intracellular signaling equivalent to a typical mutation, R206H.
Ohte S; Shin M; Sasanuma H; Yoneyama K; Akita M; Ikebuchi K; Jimi E; Maruki Y; Matsuoka M; Namba A; Tomoda H; Okazaki Y; Ohtake A; Oda H; Owan I; Yoda T; Furuya H; Kamizono J; Kitoh H; Nakashima Y; Susami T; Haga N; Komori T; Katagiri T
Biochem Biophys Res Commun; 2011 Apr; 407(1):213-8. PubMed ID: 21377447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
